Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Novocure Ltd Ord Sh (NQ: NVCR ) 16.87 UNCHANGED Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 16.87 Bid (Size) 16.50 (3) Ask (Size) 17.88 (1) Prev. Close 16.87 Today's Range 16.87 - 16.87 52wk Range 10.87 - 42.69 Shares Outstanding 103,647,871 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Breaking Down NovoCure: 4 Analysts Share Their Views July 02, 2024 Via Benzinga Novocure to Report Second Quarter 2024 Financial Results July 01, 2024 From Novocure Via Business Wire Performance YTD +17.15% +17.15% 1 Month -26.07% -26.07% 3 Month +18.05% +18.05% 6 Month +24.96% +24.96% 1 Year -59.52% -59.52% More News Read More 10 Health Care Stocks With Whale Alerts In Today's Session June 07, 2024 Via Benzinga A Closer Look at 7 Analyst Recommendations For NovoCure June 04, 2024 Via Benzinga Unveiling 8 Analyst Insights On NovoCure May 02, 2024 Via Benzinga Why NovoCure Stock Soared 18.3% This Week March 30, 2024 Via The Motley Fool Why Novocure Stock Is Jumping Today March 28, 2024 Via The Motley Fool METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival June 03, 2024 From Novocure Via Business Wire Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday May 20, 2024 Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session May 15, 2024 Via Benzinga Peeling Back The Layers: Exploring NovoCure Through Analyst Insights March 27, 2024 Via Benzinga Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 May 14, 2024 Via InvestorPlace NovoCure (NVCR) Q1 2024 Earnings Call Transcript May 03, 2024 Via The Motley Fool Topics Earnings Exposures Financial NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024 May 02, 2024 Via InvestorPlace Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon May 02, 2024 From Novocure Via Business Wire Novocure Reports First Quarter 2024 Financial Results May 02, 2024 From Novocure Via Business Wire Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 April 24, 2024 From Novocure Via Business Wire Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 April 05, 2024 From Novocure Via Business Wire 10 Health Care Stocks Whale Activity In Today's Session April 03, 2024 Via Benzinga Novocure to Report First Quarter 2024 Financial Results April 01, 2024 From Novocure Via Business Wire Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows March 27, 2024 Via Benzinga Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday March 27, 2024 Via Benzinga Topics Stocks Exposures US Equities Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment March 27, 2024 Via Investor's Business Daily 12 Health Care Stocks Moving In Wednesday's Pre-Market Session March 27, 2024 Via Benzinga METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer March 27, 2024 From Novocure Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
